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Abstract
Background:  The overall level of chromatin compaction is an important mechanism of
radiosensitivity, and modification of DNA methylation and histone deacetylation may increase
radiosensitivity by altering chromatin compaction. In this study, we investigated the effect of a
demethylating agent, a histone deacetylase(HDAC) inhibitor, and the two agents combined on
radiosensitivity in human colon and breast cancer cell lines.
Methods: In this study, we used RKO colorectal cancer cell line and MCF-7 breast cancer cell lines
and normal colon cell lines. On each of the cell lines, we used three different agents: the HDAC
inhibitor sodium butyrate(SB), the demethylating agent 5-Aza-2'-deoxycytidine(5-aza-DC), and
radiation. We then estimated the percentage of the cell survival using the XTT method and
experimented to determine if there was an augmentation in the therapeutic effect by using different
combinations of the two or three of the treatment methods.
Results: After treatment of each cell lines with 5-aza-DC, SB and 6 grays of radiation, we observed
that the survival fraction was lower after the treatment with 5-aza-DC or SB than with radiation
alone in RKO and MCF-7 cell lines(p < 0.001). The survival fraction was lowest when the two
agents, 5-aza-DC and SB were combined with radiation in both RKO and MCF-cell lines.
Conclusion: In conclusion, 5-aza-DC and SB can enhance radiosensitivity in both MCF-7 and RKO
cell lines. The combination effect of a demethylating agent and an HDAC inhibitor is more effective
than that of single agent treatment in both breast and colon cancer cell lines.
Background
Epigenetics is an important intracellular procedure that
can change the genetic information of the cells that is
transmitted during cell division without changing the
sequences of the DNA bases [1]. Of the mechanisms of
epigenetics, methylation of DNA and histone alteration
are related to carcinogenesis.
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DNA methylation is carried out by DNMT (DNA methyl-
transferase), usually when a methyl group is added to the
cytosine residue of a CpG island, which is a group of
repeated CpG sequences [2]. Aberrant methylation of
DNA has an important role in controlling genes and epi-
thelial carcinogenesis. When methylation of the CpG
island which is at the promoter region of the genetic
sequence, occurs the transcription of the gene is sup-
pressed. If hypermethylation occurs at the promoter
region of the tumor suppressor genes, transcription is
inhibited, which results in the loss of the function of the
gene. This functional loss brings about an inability to sup-
press cell proliferation, which can lead to carcinogenesis
[2-4].
Histone alteration is another epigenetic mechanism of
regulating transcription. The histone octamer consists of a
core, which is encircled by double stranded DNA to form
a nucleosome. Two enzymes are associated with histone
deacetylation – histone acetyltransferase and histone
deacetylase(HDAC) [5]. HDAC takes part in carcinogene-
sis by regulating cell cycle progression, mitosis, and tran-
scription of genes that participate in apoptosis. Recently a
great deal of research has been carried out focusing on the
inhibition of HDAC [6].
The biggest difference between the mechanisms of epige-
netics and genetics is that epigenetics can be reversed by
using certain chemical substances [1]. Also, there have
been recent reports that histone deacetylation, combined
with DNA methylation of tumor suppressor genes, can
suppress the function of genes [7-11]. According to this
mechanism, the combination of demethylating agents
and HDAC inhibitors as an ideal epigenetics treatment
modality may bring about good results.
Recently, there has been growing interests in the sub-
stances that regulate cellular radiosensitivity as a strategy
to increase tumor radiosensitivity. There are reports that
HDAC inhibitors and demethylating agents enhance radi-
osensitivity [9,12-14]. However, not much information is
known about the combined effects of HDAC inhibitors
and demethylating agents. In this experiment, human
colon and breast cancer cell lines were used to determine
the effects of the demethylation agent, 5-Aza-2'deoxycyti-
dine (5-aza-DC), and the HDAC inhibitor, sodium
butyrate (SB), and the two agents combined on radiosen-
sitivity.
Materials and methods
Cell line culture and reagents
Human colon cancer cell lines RKO (ATCC, USA), breast
cancer cell line MCF-7 (KCLB, Korea), and normal colon
cell line DDC-112 CoN (ATCC) were used. RKO and
MCF-7 cell lines were cultivated in Dulbecco's modified
Eagle's medium (DMEM)/F12 (Gibco, Invitrogen Corp.,
San Diego, California, USA) combined with 10% fetal
bovine serum and 1% penicillin/streptomycin using a
humidified cultivator that maintained 37°C and 5%
CO2. The normal cell line was cultivated using the same
cultivator in Dulbecco's modified Eagle's medium
(DMEM) combined with 10% fatal bovine serum.
After melting 5-Aza-2'-deoxycytidine (Fluka, Sigma-
Aldrich chemic GmbH, Riedstr.) in phosphate-buffered
saline, and sodium butyrate(Fluka) in sterilized distilled
water, they were stored at 20°C and used when needed.
Radiation
After 1 × 106 cells from each cell line were cultured for 24
hours in 100 mm culture dishes, they were divided into
three groups. Each group was irradiated with 4 Gy, 6 Gy,
or 4 Gy plus additional day of 4 Gy and cultured for 24 or
48 hours after irradiation. The medium used was Dul-
becco's modified Eagle's medium (DMEM)/F12(Gibco)
combined with 10% fetal bovine serum and 1% penicil-
lin/streptomycin.
Bisulfate modification and methylation-specific PCR
After being treated with 5-Aza-2'-deoxycytidin and
sodium butyrate, and after having received radiation for
the proper dose and duration, the DNA was extracted
using a QIAamp DNA Mini Kit (Qiagen, Gmbh, Hilden,
Germany). The procedure of bisulfate modification of
genomic DNA was performed as follows.
After denaturing 2 ug of DNA into 2 M NaOH, the DNA
was incubated in 30 ul of 10 mM hydroquinone(Sigma-
Aldrich, Inc., St. Louis, USA) and 520 ul of 3 M sodium
bisulfate (Sigma) for 16 hours at 50°C. Modified DNA
was filtered with a Wizard DNA clean-up system
(Promega, Madison, Wisconsin, USA) and then denatured
again to 3 M NaOH. 3 M NaOH was precipitated in 100%
ethanol and 2.5 M ammonium acetate and, then melted
in 20 ul of distilled water. AccuPrime SuperMix I (invitro-
gen, Life Technologies) was used for PCR; Modified
genomic DNA 1 ul was amplified. The product was con-
firmed with 2.5% agarose gel. PCR conditions and prim-
ers are given in Tables 1 and 2. The genes used in this
study were MINT 1, 2, 31; methylated in tumor, p16; cyc-
lin dependent kinase inhibitor 4a, p14; p-14 alternative
reading frame, E-cadherin; epithelial cadherin.
Cell proliferation assay
After 24 hours of seeding of 3 × 103 cells each DDC-112
CoN, RKO, and MCF7 in a 96-well plate, 5-Aza-2'-deoxy-
cytidin 4 uM, sodium butyrate 1 mM, and a combination
of both were added and then cultivated for 48 hours. An
assay was done using a cell proliferation kit II(XTT)(Roche
Diagnositcs GmbH, Mannheim, Germany).World Journal of Surgical Oncology 2009, 7:49 http://www.wjso.com/content/7/1/49
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Statistical analysis
For comparison of the treatment effect of radiation, the
data were converted to a log scale. Then, using SPSS ver.
13.0, the results were compared with ANOVA(Analysis of
Variance), and p values less than 0.005 were considered
significant. The average and standard deviation were not
converted to log scale in the table of statistics; original
data's average and standard deviation were documented.
Results
Determining radiation dose and culture time
We irradiated the RKO cell line with the different dose of
radiation(4G, 6G, 4G + 4G) and cultured the cells for 24
hours, 48 hours and 72 hours. Then we analyzed the cell
survival (Fig 1). For the culture time, there was significant
change between day 1 and day 2. But there was no signif-
icant change between control and day 1 or between day 2
Table 1: Conditions of MS-PCR
Denaturation Annealing Extension
Temp(°C) Time(min) Temp (°C) U/M Time(sec) Cycles Temp (°C) Time(min)
p14ARF 95 5 62/62 30 40 72 7
p16INK4a 95 5 63/63 30 40 72 7
E-cadherin 95 5 55/57 30 40 72 7
MINT1(M1) 95 5 52/52 30 37 72 7
MINT2(M2) 95 5 59/59 30 40 72 7
MINT31(M31) 95 5 62/60 30 38 72 7
Table 2: MS-PCR primers of specific genes analyzed in this study
Sense primer (5'-3') Antisense primer (5'-3')
p14ARF M GTGTTAAAGGGCGGCGTAGC AAAACCCTCACTCGCGACG
U TTTTTGGTGTTAAAGGGTGGTGTAGT CACAAAAACCCTCACTCACAACAA
p16INK4a M TTATTAGAGGGTGGGGCGGATCGC GACCCCGAACCGCGACCGTAA
U TTATTAGAGGGTGGGGTGGATTGT CAACCCCAAACCACAACCATA
E-cadherin M TTAGGTTAGAGGGTTATCGCGT TAACTAAAAATTCACCTACCGAC
U TAATTTTAGGTTAGAGGGTTATTGT CACAACCAATCAACAACACA
MINT1(M1) M AATTTTTTTATATATATTTTCGAAGC AAAAACCTCAACCCCGCG
U AATTTTTTTATATATATTTTTGAAGTGT AACAAAAAACCTCAACCCCACA
MINT2(M2) M TTGTTAAAGTGTTGAGTTCGTC AATAACGACGATTCCGTACG
U GATTTTGTTAAAGTGTTGAGTTTGTT CAAAATAATAACAACAATTCCATACA
MINT31(M31) M TGTTGGGGAAGTGTTTTTCGGC CGAAAACGAAACGCCGCG
U TAGATGTTGGGGAAGTGTTTTTTGGT TAAATACCCAAAAACAAAACACCACAWorld Journal of Surgical Oncology 2009, 7:49 http://www.wjso.com/content/7/1/49
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and day3. For the irradiation dose, 4G and 6G showed
more clear survival differences than 4G + 4G did and both
4 Gy and 6 Gy were adequate for analyzing the radiosen-
sitivity. So we chose 4G as irradiation dose and 48 hours
as culture time
CCD-112 CoN, MCF-7 and RKO cell line methylation
In the RKO cell line, all of the tumor suppressor genes
were methylated. Half were methylated in the MCF-7 cell
line; MINT 1, MINT 31, p16 were methylated and MINT
2, p14, E-cadherin were unmethylated. None were meth-
ylated in the CCD-112 CoN cell lines (Table 3).
MS-PCR results after adding 5-Aza-2'-deoxycytidine to the 
RKO cell line
In the control group, most of the genes were methylated,
but cell lines treated with 5-aza-DC showed profound
increase of unmethylated bands. (Fig 2).
MS-PCR results after adding sodium butyrate to the RKO 
cell line
Compared to the control group, there were almost no
changes in methylation status with the addition of SB (Fig
3).
XTT results after addition of sodium butyrate and 5-Aza-
2'-deoxycytidine
In the MCF-7 cell line, 87% of the cells survived after radi-
ation alone, 73% after adding 5-aza-DC, and 55.7% after
adding SB. Thus both 5-aza-DC and SB increased radio-
sensitivity, with 5-aza-DC having better results. The com-
bination of the two showed a synergistic effect, which
resulted in 45.7% cell survival (p < 0.001).
In the RKO cell line, 56.5% of the cells survived after radi-
ation alone, 47% survived with the addition of 5-aza-DC,
and a similar percentage (46%) survived with the addition
of SB. The combination of the two resulted in a 39.6% sur-
vival rate, showing the synergic effect of the agents (p <
0.001).
There was no statistical significance among survival rates
after treatment with radiation, 5-aza-DC, and SB in CCD-
112 CoN cell lines (Table 4, Fig 4).
Discussion
With the development of molecular radiobiology, recent
researches has focused on the molecules and processes
Cell survival according to different radiation dose(4G, 6G  and 4G+4G) and different culture time(24 hrs, 48 hrs and 72  hours) Figure 1
Cell survival according to different radiation 
dose(4G, 6G and 4G+4G) and different culture 
time(24 hrs, 48 hrs and 72 hours). There was significant 
difference in cell survival between 24 hrs and 48 hrs. Also 
radiation dose 4G and 6G showed more clear survival differ-
ence than 4G+4G did.
Table 3: The methylation status of each cell lines, CCD-112, 
MCF-7, RKO
CCD-112 MCF-7 RKO
MINT1 U M M
MINT2 U U M
MINT31 U M M
P16 U M M
P14 U U M
E-cadherin U U M
MS-PCR after 5'-aza-2'-deoxycytidine(5-aza-DC) treatment Figure 2
MS-PCR after 5'-aza-2'-deoxycytidine(5-aza-DC) 
treatment. In the control group, most of the genes were 
methylated, but cell lines treated with 5-aza-DC showed pro-
found increase of demethylated bands.World Journal of Surgical Oncology 2009, 7:49 http://www.wjso.com/content/7/1/49
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that influence the response of cells to radiation. Many dif-
ferent kinds of molecules are known to increase radiosen-
sitivity by influencing the procedures of cell cycle check
points, DNA repair, gene transcription, and apoptosis.
Recently, studies of epigenetic procedures such as histone
deacetylation and DNA methylation have been proposed
for enhancing the radiosensitivity of tumor cells.
Out of the many demethylating agents and HDAC inhib-
itors, we chose 5-aza-DC as the demethylating agent and
SB as the HDAC inhibitor for our study. 5-aza-DC is a sim-
ilar molecule to cytidine. Through a covalent bond to
DNMT, it decreases the rate of methylation, thus control-
ling genetic expression. SB is a short-chain fatty acid that
targets the activated region of zinc of HDAC. It has a very
short half-life [15].
Histone plays an important role in post-translational
modification carried out by histone acetyltransferase and
HDAC. Oncogenesis is related to inactivation of histone
acetyltransferase, and it is thought that hyperactivation of
HDAC suppresses the transcription of tumor suppressor
genes, therefore playing an important part in carcinogen-
esis [16]. Hypoacetylation of histone is related to the
structure of condensed chromatin; in this status, transcrip-
tion is inhibited. Hyperacetylation, on the other hand,
creates an open chromatin structure and transcription
becomes activated [17]. Inhibition of HDAC is known to
increase the radiosensitivity of tumor cells
[9,11,13,18,19]. In 1985, Arundel et al [19] reported that
SB, an HDAC inhibitor, at a dose relatively without toxic-
ity, enhanced radiosensitivity in colon cancer cell lines.
Camphausen et al [18] also reported that MS-275, an
HDAC inhibitor, increased radiosensitivy in prostate can-
cer cell lines. In this experiment, RKO cell lines showed a
56% survival rate with radiation alone, while with SB,
47% survived. In MCF-7 cell lines, radiation alone led to
a 87% survival rate, while when radiation was combined
with SB, 56% of cells survived, which proved that SB
increased radiosensitivity in both RKO and MCF-7 cell
lines.
There have been many hypotheses proposed for how
HDAC inhibitors enhances radiosensitivity. First, the
chromatic compaction has an important role in radiosen-
sitivity, and according to the degree of compaction, chro-
matin can be divided into euchromatin and
heterochromatin. Euchromatin is at a relaxed state in
which genes are actively undergoing transcription. Hete-
rochromatin contains inactivated genes, which, is at a
highly organized state. Genes with ongoing active tran-
scription are generally more sensitive to radiation, while
when chromatin condenses into a highly organic structure
where transcription is inactive, DNA becomes protected
from double strand breaks(DSB) and resistant to the effect
of radiation. Euchromatin contains histones, which are
acetylated and phosphorylated, while heterochromatin
contains deacetylated and methylated histones [9,20,21].
HDAC inhibitors can change heterochromatin into a
euchromatin state, and this mechanism is probably
involved in enhancing sensitivity to radiation. Repair of
DNA-DSB is another important factor in determining
radiosensitivity, and recently, studies have shown that
inhibition of DSB repair is the mechanism for increased
radiosensitivity with HDAC inhibitors. Expression of
γH2AX is an important marker in DSB created by ionizing
radiation. When an HDAC inhibitor is used, γH2AX
MS-PCR after sodium butyrate treatment Figure 3
MS-PCR after sodium butyrate treatment. Compared 
to the control group, there were almost no changes in meth-
ylation status with the addition of sodium butyrate.
The effect of 5-azaDC and SB on radiation (logarismic scale) Figure 4
The effect of 5-azaDC and SB on radiation (logaris-
mic scale).World Journal of Surgical Oncology 2009, 7:49 http://www.wjso.com/content/7/1/49
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expression is prolonged, and DSB repair is impeded by
HDAC inhibitors [13,22]. Chinnaiyan et al [23] reported
that HDAC inhibitors take part in down-regulation of the
enzymes, DNA-PK and Rad51, which participate in the
recovery of DSB, and this DSB recovery plays an important
role in determining radiosensitivity.
Hypermethylation of DNA is found commonly in tumor
cells, and it suppresses the function of genes that partici-
pate in tumor suppression or control the cell cycle, apop-
tosis or DNA repair [2-4]. Recent studies have shown that
demethylating agents enhance radiosensitivity. Dote et al
[14] reported that the DNA methylation inhibitor, zebu-
larine, increased the radiosensitivity of tumor cells in vivo
and in vitro and that the number of γH2AX foci increased
considerably. Our experiment showed that when the
demethylating agent 5-aza-DC was added to hypermeth-
ylated RKO cells, an unmethylated band was shown on
MS-PCR, and both MCF-7 and RKO cell lines showed
enhanced radiosensitivity. Another mechanism for the
increase in radiosensitivity caused by 5-aza-DC is reported
by Takeayashi et al [24]; 5-aza-DC can bring about the
hyperacetylation of histones regardless of DNA methyla-
tion. Also, there are some reports that demethylating
agents interfere with DNA repair [14].
In RKO cell lines, the effect of SB was similar to that of 5-
aza-DC, while in MCF-7 cell lines, SB was more effective
compared to 5-aza-DC. The function of HDAC inhibitor
is considered to be related with the methylation level of
the genes. Cameron et al [25] reported HDAC inhibitor
Trichostatin A(TSA) could not upregulate the expression
of MLH1, TIMP3, CDKN2A which is highly methylated
but TSA upregulated the expression of non-methylated
CDKN2B. Shen et al [11] also reported that the pathway
of histone deacetylation plays a major role when the
methylation of the promoter region is at low density.
Almost the entire promoter regions of the genes of RKO
cell lines were methylated, while about half were methyl-
ated in MCF-7 cell lines. This might be the reason why
MCF-7 cell lines are more susceptible to HDAC inhibitor
than RKO cell lines. Histone deacetylation and DNA
methylation are not independent epigenetic mechanisms;
they have a very close relationship and influence each
other.
There are reports that HDAC inhibitors and demethylat-
ing agents have a synergic effect [7,11,25,26]. Cameron et
al [25] reported the synergic effect of a HDAC inhibitor,
TSA, and a demethylating agent, 5-aza-DC, in re-expres-
sion of genes in RKO cell lines. Shen et al [11] also
reported that demethylation of the RASSF1α gene and re-
expression of mRNA was increased more with a combina-
tion of 5-aza-DC and SB compared to using 5-aza-DC
alone. In our experiment, the combined effect of 5-aza-
DC and SB was superior in enhancing radiosensitivity
compared to the use of each agent alone in both MCF-7
and RKO cell lines. The mechanism explaining why the
combination effect is better seems to be as follows. DNA
methylation recruits HDAC through DNMTs or methyl-
ated DNA binding proteins and facilitates histone
deacetylation [27,28]. HDAC reinforces DNA methyla-
tion through histone H3 lys9 methyltransferase. HDAC
and DNA methylation form a loop and influence each
other, thus enforcing them [28]. Therefore, through
HDAC inhibitor and demethylating agents, the DNA
methylation and histone acetylation becomes inactivated
and a synergic effect occurs. Also, the combination of SB
and 5-aza-DC facilitates the transformation of chromatin
into an activated state [8].
There are some reports that 5-aza-DC or SB increase the
radiosensitivity in other field than colon or breast cancer.
De Schutter et al [29] reported 5-aza-DC with or without
TSA could increase radiosensitivity in head and neck squa-
mous cell carcinoma cell line and Camphausen et al [18]
also reported MS-275 could increase radiosensitivity in
prostate cancer and glioma cell line.
Table 4: The effects of 5-azaDC and SB on radiation
Cell Survival %
With Radiation MCF-7 CCD-112 RKO
Control 87.2 ± 5.2 (0.97 ± 0.01) 99.1 ± 4.7 (1.00 ± 0.01) 56.5 ± 9.7 (0.87 ± 0.04)
5-azaDC 73.7 ± 9.6 (0.93 ± 0.03) 102.6 ± 3.1 (1.01 ± 0.01) 47.1 ± 4.3 (0.84 ± 0.02)
SB 55.7 ± 5.1 (0.87 ± 0.19) 98.9 ± 10.7 (1.00 ± 0.02) 46.0 ± 3.0 (0.83 ± 0.14)
SB + azaDC 45.7 ± 4.7 (0.79 ± 0.02) 95.8 ± 8.1 (0.99 ± 0.19) 38.6 ± 3.61 (0.79 ± 0.02)
P-value <0.001 0.491 <0.001
* p-value was calculated with logarism scaleWorld Journal of Surgical Oncology 2009, 7:49 http://www.wjso.com/content/7/1/49
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In this experiment, the survival rates of RKO and MCF-7
cell lines after irradiation showed significant differences.
One limitation of this experiment is that the found in
where effect of 5-aza-DC and SB were not measured under
the equal conditions.
Conclusion
5-aza-DC and SB enhanced radiosensitivity in MCF-7 and
RKO cell lines. In RKO cell lines, which are in a relatively
hypermethylated state, the effect of 5-aza-DC was similar
to that of SB; in MCF-7 cell lines, the effect of SB was better
than that of 5-aza-DC. In both cell lines, the combined
effect of a demethylating agents, and an HDAC inhibitor
showed better results than the effect of each agent used
alone. However, this experiment was performed in vitro,
and further investigation in vivo is needed.
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